The Boston Grand Hack is no longer virtual! After holding our Grand Hack online due to the Corona Virus, we will be back in person this year.
Safety will remain our priority, so join us in our return to an in-person Grand Hack!
Join MIT Hacking Medicine at our annual flagship event in Boston! This is the weekend to brainstorm and build innovative solutions with hundreds of like-minded engineers, clinicians, designers, developers and business people. Within our multi-theme event, there is sure to be a healthcare challenge for everyone!
Interested in helping out? You can partner with us, become a sponsor, or sign up to be a mentor! Email firstname.lastname@example.org for more information!
Twitter Hashtag: #GrandHack
Watch and listen to the full video below from our MIT Grand Hack in Boston from May 2019!
Bill Sibold is Executive Vice President and Head of Sanofi Genzyme, the specialty care global business unit of Sanofi. In this role, he is a member of the Sanofi Executive Committee. Previously, Bill was the Global Head of Sanofi Genzyme’s Multiple Sclerosis, Oncology and Immunology franchises, and led the preparation for the launches of two important new immunology treatments. Bill joined Sanofi Genzyme in 2011 as Senior Vice President and Head of Multiple Sclerosis, and oversaw the successful launches of its two MS treatments. As Head of Sanofi Genzyme, he leads the business’s efforts to maintain its leadership in rare diseases while continuing to grow in multiple sclerosis, oncology and immunology. Bill has more than 25 years of experience in the biopharmaceutical industry since starting his career with Eli Lilly. He held a number of leadership positions at Biogen, including driving their U.S. commercial operations in neurology, oncology and rheumatology, and general management of Biogen’s Australian and Asia-Pacific business. In addition to his time with Biogen, Bill also served as Chief Commercial Officer of Avanir Pharmaceuticals. Bill holds an MBA from Harvard Business School and a BA in Molecular Biophysics and Biochemistry from Yale University.
There is an increasing number of cancer types and subtypes that can manifest differently in patients based on multiple factors including co-morbidities and overall patient health. Customized, cross-disciplinary cancer care can help to optimize individual patient outcomes. Although healthcare professionals (HCPs), patients, and caregivers have tools available to them to help customize treatment plans for individual patients, they are not being universally implemented and more needs to be done to customize care. HCP evaluations involving patient-reported goals are not standardized and some patients are not comfortable, or able, to proactively engage in decisions around their care, which may further contribute to the problem. What can be developed to best support HCPs and patients to help them customize treatment plans that lead to optimal or better health outcomes? What can be done to help encourage consistent adoption of individualized treatment plans?
Schedule subject to change. Check back regularly for more details! All times in ET.